| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/01.WNL.0000223844.77636.29 |
| P8608 | Fatcat ID | release_jdl2gev42nbg3ptn3zabof3jf4 |
| P698 | PubMed publication ID | 16832099 |
| P2093 | author name string | Kim R | |
| Zimmerman J | |||
| Wen PY | |||
| Kesari S | |||
| Doherty L | |||
| Drappatz J | |||
| Gigas DC | |||
| Ostrowsky L | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 156-158 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas | |
| P478 | volume | 67 |
| Q36319721 | A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas |
| Q46239069 | A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q34196216 | Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group |
| Q46024830 | Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. |
| Q43224702 | Antitumoral effect of proliferation signal inhibitors |
| Q60935363 | Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma |
| Q21261315 | Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells |
| Q37108109 | Clearing the brain's cobwebs: the role of autophagy in neuroprotection |
| Q37316986 | Combination therapy for malignant glioma based on PTEN status |
| Q36909931 | Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells |
| Q54302548 | Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth |
| Q35534349 | Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status |
| Q48570615 | Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas |
| Q36544472 | Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics |
| Q34666788 | Current medical treatment of glioblastoma |
| Q37240726 | EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer |
| Q39736362 | Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells |
| Q39251444 | Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors |
| Q37471694 | Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry |
| Q37030800 | Emerging therapies for malignant glioma |
| Q37790320 | Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives |
| Q29615474 | Epidermal growth factor receptor mutations in lung cancer |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q55116204 | FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. |
| Q39509236 | Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation |
| Q37974419 | General and neurological complications of targeted therapy |
| Q34966112 | Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells |
| Q34735661 | Glial progenitors as targets for transformation in glioma |
| Q38597700 | Glioblastoma targeted therapy: updated approaches from recent biological insights |
| Q55463328 | Induction of autophagy promotes differentiation of glioma‐initiating cells and their radiosensitivity |
| Q36764876 | Inhibiting kinases in malignant gliomas |
| Q36494138 | Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs |
| Q37575528 | Insights into pharmacotherapy of malignant glioma in adults |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q35085333 | Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats |
| Q39690739 | Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins |
| Q46924389 | MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature |
| Q38089834 | Malignant glioma drug discovery – targeting protein kinases |
| Q34218761 | Medical therapy of gliomas |
| Q55457054 | MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma. |
| Q47738114 | Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data |
| Q33925544 | Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies |
| Q37079854 | Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines |
| Q33644407 | Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies |
| Q38272728 | Molecularly targeted therapies for recurrent glioblastoma: current and future targets |
| Q36829847 | Molecularly targeted therapy for malignant glioma |
| Q37974367 | Molecularly targeted therapy in neuro-oncology |
| Q35223458 | Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. |
| Q36972696 | New developments in the treatment of malignant gliomas |
| Q26795560 | Nonsurgical treatment of recurrent glioblastoma |
| Q36812355 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies |
| Q33747609 | Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma |
| Q43550717 | Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme |
| Q35112340 | Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors |
| Q37641248 | Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 |
| Q37035703 | Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy |
| Q35914525 | Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo |
| Q37187716 | RNAi screen for rapid therapeutic target identification in leukemia patients |
| Q34773159 | Rapamycin treatment for a child with germline PTEN mutation |
| Q54967719 | Repression of Septin9 and Septin2 suppresses tumor growth of human glioblastoma cells. |
| Q34132781 | Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies |
| Q40153405 | Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells |
| Q41942436 | Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme |
| Q39352989 | Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment |
| Q36650919 | Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling |
| Q34586319 | Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q26862516 | Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges |
| Q37533648 | Targeted therapy for malignant glioma patients: lessons learned and the road ahead |
| Q37771247 | Targeted therapy in the treatment of malignant gliomas |
| Q44043264 | Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience |
| Q34447846 | Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance |
| Q35381006 | Tetraspanin 8-rictor-integrin α3 complex is required for glioma cell migration |
| Q37271256 | The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis |
| Q35864082 | The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas |
| Q34610495 | The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications |
| Q38875632 | The mTOR signalling cascade: paving new roads to cure neurological disease |
| Q38205134 | The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline |
| Q38111449 | Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma |
| Q40154994 | Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells |
| Q34133033 | mTOR signaling in glioblastoma: lessons learned from bench to bedside |
Search more.